Intelligence for Dermatology Specialists

Dermatology clinical trials
recruiting in the United States

Up-to-date overview of clinical trials in atopic dermatitis, psoriasis, alopecia, hidradenitis suppurativa and other dermatology indications recruiting patients in the United States — automatically compiled from ClinicalTrials.gov. Refer eligible patients to participating research centers.

Active trials

891

US sites

Indications covered

BR trials

Loading map…

94 studies found

N/DAtopic DermatitisEczemaUS 1 site in the US

Studies of Skin Microflora in Healthy Individuals and Atopic Dermatitis Patients

National Human Genome Research Institute (NHGRI)

📍 Bethesda👥 530 participants

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Dermatite AtopicaPele Saudavel VoluntariosUS 1 site in the US

Effects of Treatments on the Microbiome in Healthy Volunteers and Patients With Atopic Dermatitis

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

📍 Bethesda👥 130 participants📅 Completion: 2027-01

View details →Refer patient →ClinicalTrials.gov ↗

N/DPsoriasisArtrite PsoriasicaDoenca de CrohnUS 1 site in the US

Stelara® and Tremfya® Pregnancy Exposure Registry: OTIS Autoimmune Diseases in Pregnancy Project

University of California, San Diego

📍 La Jolla👥 200 participants📅 Completion: 2031-02

View details →Refer patient →ClinicalTrials.gov ↗

N/DPsoriase em PlacasUS 1 site in the US

An Open-Label, Pilot Study to Evaluate the Efficacy of Narrowband Ultraviolet-B Phototherapy Three Times Weekly for Twelve Weeks in Moderate-to-Severe Psoriasis Patients

Psoriasis Treatment Center of Central New Jersey

📍 East Windsor👥 30 participants📅 Completion: 2020-01

View details →Refer patient →ClinicalTrials.gov ↗

Fase 4Psoríase em PlacasUS 1 site in the US

An Open-Label Study Evaluating Enstilar® (Calcipotriene and Betamethasone Dipropionate) Foam, 0.005%/0.064% QD in Psoriasis Patients Being Treated With Etanercept or Adalimumab

Psoriasis Treatment Center of Central New Jersey

📍 East Windsor👥 30 participants📅 Completion: 2019-12

View details →Refer patient →ClinicalTrials.gov ↗

N/DAtopic DermatitisAdverse Pregnancy OutcomesUS 1 site in the US

Dupilumab and Pregnancy Outcomes: A Retrospective Cohort Study Using Administrative Healthcare Databases (Dupi PODS)

Regeneron Pharmaceuticals

📍 Boston👥 3930 participants📅 Completion: 2027-01

View details →Refer patient →ClinicalTrials.gov ↗

Fase 4Plaque PsoriasisUS 3 sites in the US

A Phase 4, Open-Label, Multicenter Study Evaluating the Absorption and Systemic Pharmacokinetics and HPA Axis Suppression Potential of Topically Applied IDP-122 Lotion in Pediatric Subjects With Moderate to Severe Plaque Psoriasis

Bausch Health Americas, Inc.

📍 Doral, Miami, Thousand Oaks👥 45 participants📅 Completion: 2026-06

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Plaque PsoriasisUS 1 site in the US

Triamcinolone With Vitamin D Synergistic Efficacy in Psoriasis

Wright State University

📍 Fairborn👥 24 participants📅 Completion: 2026-12

View details →Refer patient →ClinicalTrials.gov ↗

N/DArtrite PsorialticaUS 2 sites in the US

Accelerating Psoriatic Arthritis Detection in Patients With Psoriasis: Direct-to-patient Administration of Screening Questionnaires (D2P Screening)

Jessica Walsh

📍 Philadelphia, Salt Lake City👥 18000 participants📅 Completion: 2025-12

View details →Refer patient →ClinicalTrials.gov ↗

N/DAtopic DermatitisPsoriasisHealthy ControlUS 1 site in the US

Longitudinal "Real-World" Changes in Skin Microbial Ecology in Atopic Dermatitis (AD) and Psoriasis (PS) Patients

University of Rochester

📍 Rochester👥 240 participants📅 Completion: 2027-04

View details →Refer patient →ClinicalTrials.gov ↗

Fase 4Psoríase em PlacasUS 1 site in the US

A Single Center Study to Evaluate the Effectiveness and Safety of ILUMYA in Combination With HALOG Ointment 0.1% for the Treatment of Moderate to Severe Plaque Psoriasis.

Psoriasis Treatment Center of Central New Jersey

📍 East Windsor👥 25 participants📅 Completion: 2021-03

View details →Refer patient →ClinicalTrials.gov ↗

Fase 4Psoriase em PlacasUS 1 site in the US

Open Label Study, Evaluating Taltz in Combination With Enstilar (Calcipotriene and Betamethasone Dipropionate) Foam in Psoriasis Patients

Psoriasis Treatment Center of Central New Jersey

📍 East Windsor👥 25 participants📅 Completion: 2021-03

View details →Refer patient →ClinicalTrials.gov ↗

N/DAtopic DermatitisUS 1 site in the US

Mechanisms of Increased Disease Severity in AD Patients With the IL-4Ra R576 Polymorphism

Boston Children's Hospital

📍 Boston👥 111 participants📅 Completion: 2027-09

View details →Refer patient →ClinicalTrials.gov ↗

N/DColite UlcerativaDoenca de CrohnArtrite ReumatoideUS 1 site in the US

Regulation of Mucosal Healing in Inflammatory Bowel Disease

Terrence A Barrett

📍 Lexington👥 60 participants📅 Completion: 2026-06

View details →Refer patient →ClinicalTrials.gov ↗

N/DMelanomaDoenca Inflamatoria IntestinalArtrite ReumatoideUS 1 site in the US

Testing of an Educational Tool for Patients With Melanoma and Concomitant Autoimmune Disease Who Are Candidates for Adjuvant Therapy With Immune Checkpoint Inhibitors: Acceptability and Usability With Patients and Providers

M.D. Anderson Cancer Center

📍 Houston👥 125 participants📅 Completion: 2027-02

View details →Refer patient →ClinicalTrials.gov ↗

N/DPlaque PsoriasisArtrite PsorialticaDoenca de CrohnUS 1 site in the US

Risankizumab Pregnancy Exposure Registry: a Prospective Observational Study on the Safety of Risankizumab Exposure in Pregnant Women and Their Offspring

AbbVie

📍 Morrisville👥 818 participants📅 Completion: 2032-06

View details →Refer patient →ClinicalTrials.gov ↗

N/DPrimary ImmunodeficiencyPsoriaseDermatite AtopicaUS 1 site in the US

Metabolic Profiling of Immune Responses in Immune-Mediated Diseases

National Institute of Allergy and Infectious Diseases (NIAID)

📍 Bethesda👥 300 participants📅 Completion: 2027-06

View details →Refer patient →ClinicalTrials.gov ↗

Fase 4PsoriaseUS 3 sites in the US

Preventing Arthritis in a Multi-Center Psoriasis At-Risk Cohort

NYU Langone Health

📍 Boston, New York, Rochester👥 176 participants📅 Completion: 2028-11

View details →Refer patient →ClinicalTrials.gov ↗

Fase 4Atopic DermatitisDisturbio do SonoUS 1 site in the US

Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis

Northwestern University

📍 Chicago👥 40 participants📅 Completion: 2025-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 4Atopic DermatitisUS 1 site in the US

Ethnic Differences in Mechanisms of Action of Dupilumab

University of Michigan

📍 Ann Arbor👥 30 participants📅 Completion: 2027-06

View details →Refer patient →ClinicalTrials.gov ↗

Fase 4Atopic DermatitisUS 1 site in the US

Single Center, Pilot Study to Evaluate the Effectiveness and Safety of Dupilumab in Combination With Narrowband UVB (nUVB) Phototherapy in the Treatment of Moderate-to-Severe Atopic Dermatitis

Psoriasis Treatment Center of Central New Jersey

📍 East Windsor👥 40 participants📅 Completion: 2024-12

View details →Refer patient →ClinicalTrials.gov ↗

N/DAge Related Macular DegenerationAllergiesAlpha Gal SyndromeUS 1 site in the US

A Single-Site Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

Sanguine Biosciences

📍 Waltham👥 20000 participants📅 Completion: 2025-10

View details →Refer patient →ClinicalTrials.gov ↗

N/DArtrite PsoriaticaUS 1 site in the US

Stronger Together Psoriatic Arthritis Wellness Study

Global Healthy Living Foundation

📍 Upper Nyack👥 100 participants📅 Completion: 2026-03

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Artrite PsoriaticaUS 14 sites in the US

Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients: a Pragmatic Trial (EVOLUTION)

University of Pennsylvania

📍 Blue Ash, Colleyville, Crossville, El Paso, Lilburn, Loxahatchee Groves, New York, Omaha, Philadelphia, Plant City, Riverview, Salt Lake City, Wheelersburg, Worcester👥 63 participants📅 Completion: 2026-10

View details →Refer patient →ClinicalTrials.gov ↗

N/DAtopic DermatitisUS 1 site in the US

CIBINQO™ Pregnancy Registry: An Observational Study of the Safety of Abrocitinib Exposure in Pregnant Women and Their Offspring

Pfizer

📍 New York👥 400 participants📅 Completion: 2027-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 4Atopic DermatitisUS 1 site in the US

Molecular Signatures of Cutaneous Dupilumab Response

University of California, San Francisco

📍 San Francisco👥 15 participants📅 Completion: 2026-02

View details →Refer patient →ClinicalTrials.gov ↗

Fase 4Psoriase do Couro CabeludoUS 1 site in the US

Immune Spatial Features of Guselkumab Cutaneous Response

University of California, San Francisco

📍 San Francisco👥 10 participants📅 Completion: 2026-06

View details →Refer patient →ClinicalTrials.gov ↗

Fase 4Psoriase VulgarisUS 1 site in the US

Correction of Psoriatic T Cell Signatures by Deucravacitinib

University of California, San Francisco

📍 San Francisco👥 25 participants📅 Completion: 2026-06

View details →Refer patient →ClinicalTrials.gov ↗

N/DArtrite ReumatoideArtrite PsorialticaPsoriaseUS 1 site in the US

Investigating Mechanisms of Participatory Autoimmune Condition Treatment (IMPACT): An Outcomes Research Registry of a Comprehensive Approach to Autoimmune Disorders

AndHealth

📍 Columbus👥 2500 participants📅 Completion: 2028-05

View details →Refer patient →ClinicalTrials.gov ↗

N/DAtopic DermatitisUS 1 site in the US

Monitoring Pregnancy and Infant Outcomes Following Tralokinumab Exposure During Pregnancy in the US and Canada - PROTECT

University of California, San Diego

📍 La Jolla👥 900 participants📅 Completion: 2035-09

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Atopic DermatitisUS 44 sites in the US

A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF-07275315 AND PF-07264660 IN ADULT PARTICIPANTS WITH MODERATE-SEVERE ATOPIC DERMATITIS

Pfizer

📍 Birmingham, Chickasha, Clarkston, Dallas, Doral, East Syracuse, Frisco, Houston, Hunt Valley, Huntington Beach, Indianapolis, Johnston, Los Angeles, Mayfield Heights, Memphis, Miami, Miami Lakes, New Albany, New York, Newport Beach, North Charleston, North Miami Beach, Northridge, Northville, Oceanside, Oklahoma City, Omaha, Orlando, Peoria, Philadelphia, Phoenix, San Antonio, San Diego, Spartanburg, St. Petersburg, Sugar Land, Tampa, Troy, Tucson, Tulsa👥 340 participants📅 Completion: 2027-03

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Atopic DermatitisUS 1 site in the US

A Phase 2b, Double-Blind, Randomized, Placebo-Controlled Trial of Cardamom and Topical Roseomonas in Atopic Dermatitis

National Institute of Allergy and Infectious Diseases (NIAID)

📍 Bethesda👥 120 participants📅 Completion: 2027-01

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Juvenile Psoriatic ArthritisUS 9 sites in the US

Open-label, Randomized, Assessor-blinded, Efficacy, Safety, Tolerability, and Pharmacokinetics Study of Subcutaneous Risankizumab With an Adalimumab Reference Arm in Children With Active Juvenile Psoriatic Arthritis

AbbVie

📍 Austin, Chapel Hill, Cleveland, Hollywood, Indianapolis, Little Rock, Minneapolis, Valhalla, Washington D.C.👥 40 participants📅 Completion: 2028-10

View details →Refer patient →ClinicalTrials.gov ↗

N/DGeneralized Pustular PsoriasisUS 1 site in the US

CorEvitas Generalized Pustular Psoriasis (GPP) Drug Safety and Effectiveness Registry

CorEvitas

📍 Waltham👥 200 participants📅 Completion: 2099-12

View details →Refer patient →ClinicalTrials.gov ↗

N/DAtopic DermatitisUS 1 site in the US

Registry for Systemic Eczema Treatments

Johns Hopkins University

📍 Baltimore👥 400 participants📅 Completion: 2030-12

View details →Refer patient →ClinicalTrials.gov ↗

N/DAtopic DermatitisUS 1 site in the US

CorEvitas International Adolescent Atopic Dermatitis (AD) Drug Safety and Effectiveness Registry

CorEvitas

📍 Waltham👥 1500 participants📅 Completion: 2099-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Dermatite AtopicaUS 42 sites in the US

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment

Sanofi

📍 Albuquerque, Ann Arbor, Arlington, Bellaire, Birmingham, Bowling Green, Boynton Beach, Charleston, Cheyenne, Chicago, Cincinnati, Dallas, Doral, East Windsor, Encino, Fremont, Indianapolis, Jacksonville, Long Beach, Los Angeles, Metairie, Mill Creek, Milwaukee, New York, Newport Beach, Norfolk, North Little Rock, Northville, Ogden, Omaha, Philadelphia, Portland, San Diego, Scottsdale, Skokie, St. Petersburg, Tampa, Wheat Ridge👥 390 participants📅 Completion: 2026-09

View details →Refer patient →ClinicalTrials.gov ↗

N/DAtopic DermatitisUS 1 site in the US

Topical Treatment for Atopic Dermatitis

Wake Forest University Health Sciences

📍 Winston-Salem👥 30 participants📅 Completion: 2027-07

View details →Refer patient →ClinicalTrials.gov ↗

N/DAtopic DermatitisGravidezUS 1 site in the US

A US-Prospective, Registry-Based, Observational, Exposure Cohort Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population

Incyte Corporation

📍 Morrisville👥 958 participants📅 Completion: 2033-08

View details →Refer patient →ClinicalTrials.gov ↗

N/DAlergia AlimentarAlergia Alimentar Com Dermatite AtopicaDermatite AtopicaUS 1 site in the US

Michigan Food and Atopic Dermatitis (M-FAD) Program - Molecular Analytics Project

University of Michigan

📍 Ann Arbor👥 200 participants📅 Completion: 2027-03

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Atopic DermatitisUS 14 sites in the US

A Phase 3 Multi-center Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children (Age 2 to <12 Years) and Infants (Age 6 Months to <2 Years) With Moderate-to-severe Atopic Dermatitis. The Trial is Randomized, Double-blind, Placebo-controlled, and Parallel-group for Children (Age 2 to <12 Years) and Open-label and Single-group for Infants (Age 6 Months to <2 Years)

LEO Pharma

📍 Birmingham, Charleston, Jacksonville, Macon, Miami, Norfolk, North Little Rock, Palo Alto, Portland, Sacramento, San Diego, Tampa, Tulsa, Waterford👥 195 participants📅 Completion: 2028-04

View details →Refer patient →ClinicalTrials.gov ↗

Fase 4Plaque PsoriasisUS 2 sites in the US

A Study to Evaluate the Safety and Efficacy of Bimekizumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed IL-17 or IL-23 Therapies

Icahn School of Medicine at Mount Sinai

📍 East Windsor, New York👥 60 participants📅 Completion: 2026-03

View details →Refer patient →ClinicalTrials.gov ↗

N/DArtrite ReumatoideArtrite PsoriaticaEspondilite AnquilosanteUS 1 site in the US

Title of Study: Eating Habits and Symptom Severity in Autoimmune Diseases: a Patient Survey

University of Central Florida

📍 Orlando👥 500 participants📅 Completion: 2025-07

View details →Refer patient →ClinicalTrials.gov ↗

N/DPsoriaseUS 1 site in the US

Mediterranean Diet vs no Dietary Intervention for Improving Signs and Symptoms of Psoriasis in Patients Treated With Anti-IL-17 or Anti-IL-23 Inhibitors

University Hospitals Cleveland Medical Center

📍 Cleveland👥 36 participants📅 Completion: 2026-07

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Psoríase em Placas Moderada a GraveUS 2 sites in the US

A Multicenter, Randomized, Parallel-Group, Double-Blind, Active-Controlled Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis

UCB Biopharma SRL

📍 Kew Gardens, Miami👥 168 participants📅 Completion: 2030-11

View details →Refer patient →ClinicalTrials.gov ↗

Fase 4Artrite PsoriaticaEspondiloartrite AxialUS 3 sites in the US

A Randomized, Placebo-controlled, Multicenter, Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis (UP-SPOUT)

CARE ARTHRITIS LTD.

📍 Cleveland, Philadelphia, Portland👥 100 participants📅 Completion: 2028-10

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Atopic DermatitisUS 26 sites in the US

A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

AbbVie

📍 Arlington, Boise, Bowling Green, Canal Winchester, Charleston, Chicago, Coral Gables, El Paso, Fairborn, Indianapolis, Lanham, Little Rock, Mansfield, Milwaukee, Morgantown, Normal, Omaha, Palo Alto, Portland, Rockville, Sacramento, San Antonio, Savannah, South Jordan, St Louis👥 675 participants📅 Completion: 2030-07

View details →Refer patient →ClinicalTrials.gov ↗

N/DDermatite AtopicaPruridoUS 1 site in the US

Efficacy of 3% Kanuka Oil Versus 1% Hydrocortisone Cream in the Treatment of Patients With Mild Atopic Dermatitis

Nexgen Dermatologics, Inc.

📍 Boynton Beach👥 60 participants📅 Completion: 2025-03

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Atopic DermatitisUS 8 sites in the US

Safety and Efficacy of Topical Bacteriotherapy for Atopic Dermatitis Using Staphylococcus Hominis A9

National Institute of Allergy and Infectious Diseases (NIAID)

📍 Chicago, Cincinnati, Denver, Madison, New York, Rochester, San Diego👥 86 participants📅 Completion: 2027-02

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Psoríase em PlacasArtrite PsoriaticaUS 6 sites in the US

A Phase 3b Exploratory Multicenter Open-Label Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis

UCB Biopharma SRL

📍 Ann Arbor, Birmingham, Fountain Valley, Pittsburgh, Rochester, Tampa👥 90 participants📅 Completion: 2028-03

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Healthy ParticipantsAtopic DermatitisUS 1 site in the US

A PHASE 1, FIRST IN HUMAN, RANDOMIZED, DOUBLE-BLIND, SPONSOROPEN, PLACEBO-CONTROLLED, SINGLE- AND MULTIPLE DOSE ESCALATION, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF PF-07832837 IN HEALTHY PARTICIPANTS AND PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

Pfizer

📍 Anaheim👥 119 participants📅 Completion: 2027-06

View details →Refer patient →ClinicalTrials.gov ↗

N/DPsoriaseUS 1 site in the US

Use of Total-Body PET to Quantify Systemic and Cutaneous Inflammation in Psoriasis Patients Before and After Intervention With a Nutritionally Balanced Diet

University of California, Davis

📍 Sacramento👥 5 participants📅 Completion: 2026-09

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Doenca de CrohnColite UlcerativaArtrite PsoriaticaUS 4 sites in the US

A Phase 3, Multicenter, Open-label, Basket, LTE Study to Evaluate the Safety of Guselkumab in Pediatric Participants With Crohn's Disease, Ulcerative Colitis, or Juvenile Psoriatic Arthritis

Janssen Research & Development, LLC

📍 Atlanta, Cincinnati, Indianapolis, Salt Lake City👥 196 participants📅 Completion: 2031-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Artrite PsoriaticaUS 21 sites in the US

A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002)

Takeda

📍 Baltimore, Boca Raton, Bowling Green, Charlotte, Cleveland, Covina, Duncansville, Fort Worth, Hialeah, Houston, Kansas City, Lansing, Lawrenceville, Mesa, Phoenix, Plantation, Seattle, Skokie, St. Petersburg, The Woodlands, Tucson👥 600 participants📅 Completion: 2028-01

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Dermatite AtopicaUS 9 sites in the US

A 16-WEEK, MULTICENTER, INTERVENTIONAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ABROCITINIB IN CHILDREN 6 TO LESS THAN 12 YEARS OF AGE WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS

Pfizer

📍 Birmingham, Charleston, Greenville, Indianapolis, Jacksonville, North Little Rock, San Diego, St Louis👥 150 participants📅 Completion: 2027-05

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Artrite PsoriaticaUS 20 sites in the US

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-experienced Participants With Active Psoriatic Arthritis

Janssen Research & Development, LLC

📍 Albuquerque, Allen, Charlotte, Clearwater, Dallas, DeBary, Duncansville, Eagan, Glendale, Hagerstown, Irving, Jonesboro, Mesa, New Port Richey, Oklahoma City, Plantation, Seattle, Tampa, Tomball, Waco👥 750 participants📅 Completion: 2028-10

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Atopic DermatitisUS 12 sites in the US

A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis

Incyte Corporation

📍 Birmingham, Boise, Bolivar, Cumming, Denver, Detroit, Hollywood, Marriottsville, Milwaukee, Normal, Phoenix, Saint Joseph👥 240 participants📅 Completion: 2028-05

View details →Refer patient →ClinicalTrials.gov ↗

Fase 4Psoríase em PlacasObesidade ou SobrepesoUS 42 sites in the US

A Phase 4, Prospective, Open-Label, Single Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab in Adult Participants With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight in Clinical Practice

Eli Lilly and Company

📍 Ann Arbor, Bay City, Bellaire, Bellevue, Boardman, Bowling Green, Brighton, Burien, Caledonia, Cary, Columbia, Dallas, Douglasville, East Windsor, Fort Myers, Fountain Valley, Fremont, Hialeah, Hoboken, Hollywood, Houston, Huntersville, Indianapolis, Layton, Los Angeles, Myrtle Beach, New York, Northridge, Pflugerville, Phoenix, Plainfield, Plymouth Meeting, Portland, Portsmouth, Reno, Rockville, San Antonio, Smyrna, Tampa, Webster, Wellington👥 200 participants📅 Completion: 2028-05

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Atopic DermatitisUS 23 sites in the US

A Phase II, Multicenter, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of RO7790121 in Patients With Moderate to Severe Atopic Dermatitis

Hoffmann-La Roche

📍 Alpharetta, Arlington, Atlanta, Camp Hill, Columbus, Dallas, Doral, Hoboken, Indianapolis, Kew Gardens, Los Angeles, Minneapolis, New Albany, New York, Oklahoma City, Portland, San Antonio, Springfield, Tampa, Troy👥 160 participants📅 Completion: 2027-04

View details →Refer patient →ClinicalTrials.gov ↗

Fase 4Artrite PsoriaticaSobrepeso ou ObesidadeUS 53 sites in the US

A Phase 4, Prospective, Open-Label, Single-Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab in Adult Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice.

Eli Lilly and Company

📍 Apple Valley, Avondale, Chandler, Chicago, Colleyville, Covina, Cumberland, Flagstaff, Fort Worth, Gilbert, Glendale, Hagerstown, Houston, Huntington Beach, Irving, Jackson, Kalispell, Katy, Kissimmee, La Mesa, Lake Charles, Margate, Marietta, Mesa, Miami Beach, Middleburg Heights, Murfreesboro, New Albany, Palm Beach Gardens, Phoenix, Riverside, Rochester, Saint Clair Shores, Salisbury, San Diego, Santa Monica, Schaumburg, Seattle, Skokie, Spokane Valley, Sun City, Tampa, Temecula, The Woodlands, Tomball, Tucson, Tujunga, Tulsa, Waycross, Whittier, Willowbrook👥 200 participants📅 Completion: 2027-11

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Plaque PsoriasisPsoriatic ArthritisAxial SpondyloarthritisUS 4 sites in the US

A Multicenter Open-label, Prospective Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

UCB Biopharma SRL

📍 Durham, Milwaukee, Santa Monica, South Miami👥 20 participants📅 Completion: 2027-05

View details →Refer patient →ClinicalTrials.gov ↗

N/DAtopic DermatitisUS 1 site in the US

A Prospective, Multi-center Observational Study Characterizing Clinical Outcomes of Patients Receiving Abrocitinib for Moderate-to-severe Atopic Dermatitis Who Had an Inadequate Response (or Intolerance) to ≤2 Previous Biologic Therapies Approved for Moderate-to-severe Atopic Dermatitis

Pfizer

📍 New York👥 150 participants📅 Completion: 2026-09

View details →Refer patient →ClinicalTrials.gov ↗

Fase 4Atopic DermatitisUS 1 site in the US

A Phase IV, Non-randomized, Open-label Multinational Trial to Assess the Mechanism of Action for Lebrikizumab in Moderate-to-severe Atopic Dermatitis

Johann E Gudjonsson MD PhD

📍 Folsom👥 48 participants📅 Completion: 2027-07

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Atopic DermatitisUS 22 sites in the US

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Platform Study to Assess the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

Novartis Pharmaceuticals

📍 Arlington, Atlanta, Birmingham, Brighton, Brooklyn, Cypress, Dallas, Fort Smith, Fountain Valley, Houston, Los Angeles, Louisville, Macon, Miami, Sacramento, Saint Joseph, San Antonio, Santa Ana, Santa Monica, Troy, Washington D.C.👥 224 participants📅 Completion: 2028-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Psoríase em PlacasUS 23 sites in the US

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Deucravacitinib in Adolescent Participants (12 Years to Less Than 18 Years) With Moderate to Severe Plaque Psoriasis

Bristol-Myers Squibb

📍 Atlanta, Canton, Fremont, Goodlettsville, Hickory, Indianapolis, Las Vegas, Los Angeles, Margate, Mayfield Heights, Miami, Miami Lakes, Milford, Mill Creek, Nashville, Northridge, Philadelphia, Rockville, San Antonio, Sandy Springs, Tampa, Walnut Creek, Wheat Ridge👥 366 participants📅 Completion: 2034-08

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Atopic DermatitisPsoriase em PlacasUS 2 sites in the US

Phase 1b Randomized, Double Blind, Placebo-controlled Study to Evaluate Safety, Tolerability and Pharmacokinetics of LPX-TI641 in Patients With Atopic Dermatitis and Psoriasis

LAPIX Therapeutics Inc.

📍 Dallas, Fargo👥 48 participants📅 Completion: 2026-04

View details →Refer patient →ClinicalTrials.gov ↗

N/DAtopic DermatitisUS 2 sites in the US

Sodium in the Skin and Atopic Dermatitis

University of California, San Francisco

📍 San Francisco👥 90 participants📅 Completion: 2028-08

View details →Refer patient →ClinicalTrials.gov ↗

N/DPsoriaseUS 1 site in the US

The Deucravacitinib Pregnancy Exposure Study: A Prospective Observational Study of Deucravacitinib Safety in Pregnancy

Bristol-Myers Squibb

📍 La Jolla👥 900 participants📅 Completion: 2029-02

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Plaque PsoriasisUS 1 site in the US

A Phase I, Randomized, Double-blind, Placebo Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of ASC50 Tablets in Healthy Adult Participants and Adult Participants With Mild to Moderate Plaque Psoriasis

Ascletis Pharma (China) Co., Limited

📍 Miami👥 94 participants📅 Completion: 2026-06

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Atopic DermatitisUS 16 sites in the US

A Phase 2b, Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group, Dose-finding Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

Inmagene LLC

📍 Anderson, Burien, Charlotte, Columbus, Fargo, Kew Gardens, Lancaster, Los Angeles, Mayfield Heights, New York, Ocala, Portland, Rolling Meadows, Southlake, Tampa, Woodbury👥 220 participants📅 Completion: 2027-10

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Atopic DermatitisUS 33 sites in the US

A Phase 2, Parallel-arm, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of BFB759 in Patients With Atopic Dermatitis (COMPASS 2-AD)

Bluefin Biomedicine, Inc.

📍 Boca Raton, Brighton, Burien, Charlotte, Covington, Dallas, Douglasville, Encino, Hackensack, Huntington Beach, Lancaster, Las Vegas, Los Angeles, Mayfield Heights, Metairie, Missoula, Missouri City, New York, Norfolk, North Miami Beach, Phoenix, Pittsburgh, Plainfield, Reno, Rocklin, Saint Joseph, San Antonio, Southlake, Sparks, Tampa, West Hills, Winter Park, Woodbury👥 225 participants📅 Completion: 2027-03

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Atopic DermatitisUS 1 site in the US

Clinical Evaluation of the Skin Microbiome and the Efficacy of an Over-The-Counter (OTC) Drug for Atopic Dermatitis

Good Molecules, LLC

📍 New York👥 36 participants📅 Completion: 2026-11

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Atopic DermatitisUS 20 sites in the US

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy and Safety of EVO756 in Adults With Atopic Dermatitis

Evommune, Inc.

📍 Bay City, Boca Raton, Bowling Green, Clarksville, Coral Gables, East Syracuse, Fremont, Hollywood, Lewisville, Los Angeles, Murfreesboro, New York, Pasadena, Rochester, Rockville, San Antonio, South Jordan, Tampa, Troy, Wilmington👥 120 participants📅 Completion: 2026-07

View details →Refer patient →ClinicalTrials.gov ↗

N/DRheumatoid ArthritisSjogren SyndromeSystemic Lupus ErythematosusUS 1 site in the US

Transforming Health Habits: Evaluating an Online Wellness Program for Individuals With Rheumatological Conditions

Terry L. Wahls

📍 Iowa City👥 200 participants📅 Completion: 2027-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Atopic DermatitisUS 2 sites in the US

An Extension Study To Evaluate the Long-Term Safety and Efficacy of Afimkibart (RO7790121) in Patients With Atopic Dermatitis Who Participated in Previous Afimkibart Clinical Trials

Hoffmann-La Roche

📍 Camp Hill, Troy👥 120 participants📅 Completion: 2033-02

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Dermatite AtopicaUS 10 sites in the US

A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-95597528 for the Treatment of Adult Participants With Moderate to Severe Atopic Dermatitis

Janssen Research & Development, LLC

📍 Coral Gables, Fargo, Fountain Valley, Houston, Indianapolis, Philadelphia, Portland, Rolling Meadows, San Antonio, Santa Ana👥 180 participants📅 Completion: 2028-02

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Plaque PsoriasisUS 8 sites in the US

A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Zasocitinib in Pediatric Participants Aged 4 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis

Takeda

📍 Canton, Chula Vista, Fairborn, Fountain Valley, Hialeah, Mayfield Heights, Rolling Meadows, San Antonio👥 110 participants📅 Completion: 2033-01

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Hiper Ige Sindrome Stat3Lupus Eritematoso SistemicoDermatite AtopicaUS 1 site in the US

A Pilot Study to Evaluate the Safety and Tolerability of Baricitinib in Patients With Job s Syndrome With Lupus-like Disease and/or Atopic Dermatitis

National Institute of Allergy and Infectious Diseases (NIAID)

📍 Bethesda👥 20 participants📅 Completion: 2030-10

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Atopic DermatitisUS 33 sites in the US

A Randomized, Double-Blind, Vehicle-Controlled (Period 1) and Open-Label (Period 2) Phase 3 Study to Investigate the Safety and Efficacy of Tapinarof Cream, 1% in Pediatric Participants Ages 3 Months to < 24 Months With Atopic Dermatitis

Organon and Co

📍 Auburn Hills, Bellaire, Birmingham, Boca Raton, Bowling Green, Bryant, Castle Rock, Charleston, Cumming, Dallas, Fairborn, Indianapolis, Jacksonville, Kew Gardens, Los Angeles, Meridian, New Brighton, New York, North Charleston, Oklahoma City, Plainfield, Portland, Reno, Ridgeland, Rockville, Sacramento, Saint Joseph, San Diego, Southlake, Spokane, The Bronx, Thousand Oaks, Wellington👥 180 participants📅 Completion: 2028-01

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Atopic DermatitisUS 18 sites in the US

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Moderate to Severe Atopic Dermatitis

UCB Biopharma SRL

📍 Boca Raton, Bowling Green, Chicago, Coral Gables, Dallas, Frisco, Miami, New Albany, Omaha, Philadelphia, Santa Monica, Savannah, Sugar Land, The Bronx, Troy, Wheaton👥 160 participants📅 Completion: 2028-03

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Artrite PsoriaticaUS 1 site in the US

A Phase 3, Multicenter, Long-Term Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Either Biologic DMARD-Naïve or Biologic DMARD-Experienced, Including Those With Inadequate Response to Biologic DMARDs

Takeda

📍 Fountain Valley👥 1182 participants📅 Completion: 2029-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Artrite PsoriaticaEspondiloartrite AxialUS 20 sites in the US

An Open-label, Randomized, Parallel-group, Noninferiority Study to Evaluate the Pharmacokinetics of Bimekizumab Administered Intravenously or as a Subcutaneous Injection in Participants With Active Psoriatic Arthritis and/or Active Axial Spondyloarthritis

UCB Biopharma SRL

📍 Albuquerque, Apple Valley, Beckley, Bellevue, Colleyville, Covina, Duncansville, Fort Collins, Jackson, Lansing, Mesquite, Peoria, Plano, Riverside, San Leandro, South Miami, Temecula, West Long Branch, Whittier👥 392 participants📅 Completion: 2028-09

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Plaque PsoriasisUS 20 sites in the US

A Multicenter, Randomized, Double-blinded, Placebo-controlled, Dose-range Finding Study of ORKA-001 in Participants With Moderate-to-Severe Plaque Psoriasis

Oruka Therapeutics, Inc.

📍 Chapel Hill, Cleveland, Coral Gables, Frisco, Houston, Kew Gardens, Los Angeles, Mason, Norfolk, North Little Rock, Philadelphia, Phoenix, Plainfield, Portland, Rockville, Rolling Meadows, San Diego, Webster👥 160 participants📅 Completion: 2028-12

View details →Refer patient →ClinicalTrials.gov ↗

N/DAtopic DermatitisUS 35 sites in the US

Atopic Dermatitis Disease Registry of Adult and Adolescent Patients Initiating or Switching Systemic Treatments

Sanofi

📍 Ann Arbor, Auburn Hills, Bakersfield, Bay City, Birmingham, Bolivar, Caledonia, Dallas, Doral, Falls Church, Fargo, Fort Worth, Fremont, Gilbert, Huntersville, Kirksville, Las Vegas, Lincoln, Los Angeles, Macon, Mason, Montgomery, North Chicago, North Miami Beach, Northridge, Oakland, Pomona, Portsmouth, San Diego, Savannah, Spartanburg, Sugar Land, Warwick, Waterford, Wheat Ridge👥 1000 participants📅 Completion: 2034-01

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Artrite PsoriasicaUS 14 sites in the US

A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-88545223 For the Treatment of Participants With Active Psoriatic Arthritis

Janssen Research & Development, LLC

📍 Allen, Charlotte, Cutler Bay, Evansville, Huntington Beach, Marietta, Middleburg Heights, Palmetto Bay, Philadelphia, San Diego, Searcy, Tampa, Willowbrook, Winter Park👥 240 participants📅 Completion: 2027-08

View details →Refer patient →ClinicalTrials.gov ↗

N/DGut MicrobiomeEczemaUS 1 site in the US

Flourish Study: A Randomized, Three-Arm Longitudinal Clinical Study of Microbiome-Guided Interventions in Cesarean-Born Infants

Seeding Inc

📍 Austin👥 250 participants📅 Completion: 2028-09

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Atopic DermatitisUS 1 site in the US

A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Moderate to Severe Atopic Dermatitis (SIERRA1)

Corvus Pharmaceuticals, Inc.

📍 South San Francisco👥 200 participants📅 Completion: 2027-09

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Psoríase em PlacasUS 7 sites in the US

An Open-label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of ORKA-001 in Participants With Moderate-to-Severe Plaque Psoriasis

Oruka Therapeutics, Inc.

📍 Bowling Green, Coral Gables, Los Angeles, New York, Rockville, San Diego, Santa Ana👥 80 participants📅 Completion: 2029-01

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Atopic DermatitisEczemaUS 1 site in the US

A Phase 1a/1b, Double-Blind, Randomized, Placebo-Controlled, Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234 in Healthy Volunteers and Subjects With Moderate to Severe Atopic Dermatitis.

Arcutis Biotherapeutics, Inc.

📍 Fair Lawn👥 125 participants📅 Completion: 2028-04

View details →Refer patient →ClinicalTrials.gov ↗

N/DPsoriaseUS 1 site in the US

A Decentralized, Randomized Interventional Study to Evaluate the Impact of an Over-the-Counter Magnolia Officinalis Oral Supplement on Blood Biomarkers of Immune Activation in Subjects With Psoriasis

Sirt3 LLC

📍 Englewood👥 100 participants📅 Completion: 2029-09

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Hidradenite SupurativaUS 79 sites in the US

A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

AbbVie

📍 Arlington, Bellaire, Birmingham, Boca Raton, Boise, Boston, Bountiful, Bowling Green, Brandon, Caledonia, Canton, Charleston, Charlotte, Charlottesville, Chicago, Clarkston, Columbus, Coral Gables, Dallas, Delray Beach, Durham, East Syracuse, Encino, Farmington, Fayetteville, Fountain Hills, Hershey, Hollywood, Hot Springs, Huntington Beach, Indianapolis, Kirksville, Knoxville, Las Vegas, Leawood, Lee's Summit, Los Angeles, Lynchburg, Margate, Mason, Medina, Mill Creek, Murray, New Haven, New Hyde Park, New York, Norfolk, North Little Rock, Oklahoma City, Philadelphia, Phoenix, Plano, Portland, Quincy, Reno, Rocklin, Rogers, Sacramento, Saint Joseph, Scottsdale, Skokie, Springville, St Louis, Tampa, Thousand Oaks, Tucson, Waterford, Webster, West Lafayette, Worcester👥 1328 participants📅 Completion: 2028-03

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Alopecia AreataUS 26 sites in the US

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

AbbVie

📍 Arlington, Bellaire, Boca Raton, Cedar Park, Clarkston, Cleveland, Dallas, Fountain Valley, Hollywood, Indianapolis, Los Angeles, Margate, Mason, Miami, Murfreesboro, New Orleans, New York, Omaha, Portland, Reno, Sacramento, Spartanburg, Tampa, Thousand Oaks👥 1500 participants📅 Completion: 2030-04

View details →Refer patient →ClinicalTrials.gov ↗

Fase 4Dermatite AtópicaUS 3 sites in the US

A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden

Eli Lilly and Company

📍 Bay City, Encinitas, Litchfield Park👥 200 participants📅 Completion: 2026-09

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Psoríase em PlacasUS 82 sites in the US

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

Bristol-Myers Squibb

📍 Alpharetta, Anderson, Arlington, Auburn Hills, Boca Raton, Bowling Green, Brighton, Camp Hill, Canton, Cary, Clinton Township, Coral Gables, Covington, Cypress, Dallas, Encinitas, Encino, Evansville, Fairborn, Fayetteville, Fremont, Greenville, Huntington Beach, Indianapolis, Kew Gardens, Lake Charles, Los Angeles, Louisville, Maitland, Mason, Mayfield Heights, Medford, Medina, Metairie, Miami, Milford, Mill Creek, Murfreesboro, New Albany, New Brighton, New City, North Las Vegas, Northridge, Ocala, Oklahoma City, Palmdale, Pasadena, Phoenix, Pittsburgh, Pomona, Portland, Portsmouth, Rochester, Rockville, Rogers, Sacramento, San Antonio, Santa Clarita, Santa Monica, Savannah, Scottsdale, Sherman Oaks, Skokie, Spokane, Stony Brook, Sweetwater, Tempe, The Bronx, Troy, Walnut Creek, Webster, Wilmington👥 3040 participants📅 Completion: 2031-01

View details →Refer patient →ClinicalTrials.gov ↗

Questions or requests?

Data deletion (LGPD/GDPR), partnerships, referrals, or any other matter.

Dermatology clinical trialsrecruiting in the United States

Studies of Skin Microflora in Healthy Individuals and Atopic Dermatitis Patients

Effects of Treatments on the Microbiome in Healthy Volunteers and Patients With Atopic Dermatitis

Stelara® and Tremfya® Pregnancy Exposure Registry: OTIS Autoimmune Diseases in Pregnancy Project

An Open-Label, Pilot Study to Evaluate the Efficacy of Narrowband Ultraviolet-B Phototherapy Three Times Weekly for Twelve Weeks in Moderate-to-Severe Psoriasis Patients

An Open-Label Study Evaluating Enstilar® (Calcipotriene and Betamethasone Dipropionate) Foam, 0.005%/0.064% QD in Psoriasis Patients Being Treated With Etanercept or Adalimumab

Dupilumab and Pregnancy Outcomes: A Retrospective Cohort Study Using Administrative Healthcare Databases (Dupi PODS)

A Phase 4, Open-Label, Multicenter Study Evaluating the Absorption and Systemic Pharmacokinetics and HPA Axis Suppression Potential of Topically Applied IDP-122 Lotion in Pediatric Subjects With Moderate to Severe Plaque Psoriasis

Triamcinolone With Vitamin D Synergistic Efficacy in Psoriasis

Accelerating Psoriatic Arthritis Detection in Patients With Psoriasis: Direct-to-patient Administration of Screening Questionnaires (D2P Screening)

Longitudinal "Real-World" Changes in Skin Microbial Ecology in Atopic Dermatitis (AD) and Psoriasis (PS) Patients

A Single Center Study to Evaluate the Effectiveness and Safety of ILUMYA in Combination With HALOG Ointment 0.1% for the Treatment of Moderate to Severe Plaque Psoriasis.

Open Label Study, Evaluating Taltz in Combination With Enstilar (Calcipotriene and Betamethasone Dipropionate) Foam in Psoriasis Patients

Mechanisms of Increased Disease Severity in AD Patients With the IL-4Ra R576 Polymorphism

Regulation of Mucosal Healing in Inflammatory Bowel Disease

Testing of an Educational Tool for Patients With Melanoma and Concomitant Autoimmune Disease Who Are Candidates for Adjuvant Therapy With Immune Checkpoint Inhibitors: Acceptability and Usability With Patients and Providers

Risankizumab Pregnancy Exposure Registry: a Prospective Observational Study on the Safety of Risankizumab Exposure in Pregnant Women and Their Offspring

Metabolic Profiling of Immune Responses in Immune-Mediated Diseases

Preventing Arthritis in a Multi-Center Psoriasis At-Risk Cohort

Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis

Ethnic Differences in Mechanisms of Action of Dupilumab

Single Center, Pilot Study to Evaluate the Effectiveness and Safety of Dupilumab in Combination With Narrowband UVB (nUVB) Phototherapy in the Treatment of Moderate-to-Severe Atopic Dermatitis

A Single-Site Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

Stronger Together Psoriatic Arthritis Wellness Study

Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients: a Pragmatic Trial (EVOLUTION)

CIBINQO™ Pregnancy Registry: An Observational Study of the Safety of Abrocitinib Exposure in Pregnant Women and Their Offspring

Molecular Signatures of Cutaneous Dupilumab Response

Immune Spatial Features of Guselkumab Cutaneous Response

Correction of Psoriatic T Cell Signatures by Deucravacitinib

Investigating Mechanisms of Participatory Autoimmune Condition Treatment (IMPACT): An Outcomes Research Registry of a Comprehensive Approach to Autoimmune Disorders

Monitoring Pregnancy and Infant Outcomes Following Tralokinumab Exposure During Pregnancy in the US and Canada - PROTECT

A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF-07275315 AND PF-07264660 IN ADULT PARTICIPANTS WITH MODERATE-SEVERE ATOPIC DERMATITIS

A Phase 2b, Double-Blind, Randomized, Placebo-Controlled Trial of Cardamom and Topical Roseomonas in Atopic Dermatitis

Open-label, Randomized, Assessor-blinded, Efficacy, Safety, Tolerability, and Pharmacokinetics Study of Subcutaneous Risankizumab With an Adalimumab Reference Arm in Children With Active Juvenile Psoriatic Arthritis

CorEvitas Generalized Pustular Psoriasis (GPP) Drug Safety and Effectiveness Registry

Registry for Systemic Eczema Treatments

CorEvitas International Adolescent Atopic Dermatitis (AD) Drug Safety and Effectiveness Registry

Topical Treatment for Atopic Dermatitis

A US-Prospective, Registry-Based, Observational, Exposure Cohort Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population

Michigan Food and Atopic Dermatitis (M-FAD) Program - Molecular Analytics Project

A Study to Evaluate the Safety and Efficacy of Bimekizumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed IL-17 or IL-23 Therapies

Title of Study: Eating Habits and Symptom Severity in Autoimmune Diseases: a Patient Survey

Mediterranean Diet vs no Dietary Intervention for Improving Signs and Symptoms of Psoriasis in Patients Treated With Anti-IL-17 or Anti-IL-23 Inhibitors

A Multicenter, Randomized, Parallel-Group, Double-Blind, Active-Controlled Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis

A Randomized, Placebo-controlled, Multicenter, Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis (UP-SPOUT)

A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

Efficacy of 3% Kanuka Oil Versus 1% Hydrocortisone Cream in the Treatment of Patients With Mild Atopic Dermatitis

Safety and Efficacy of Topical Bacteriotherapy for Atopic Dermatitis Using Staphylococcus Hominis A9

A Phase 3b Exploratory Multicenter Open-Label Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis

Use of Total-Body PET to Quantify Systemic and Cutaneous Inflammation in Psoriasis Patients Before and After Intervention With a Nutritionally Balanced Diet

A Phase 3, Multicenter, Open-label, Basket, LTE Study to Evaluate the Safety of Guselkumab in Pediatric Participants With Crohn's Disease, Ulcerative Colitis, or Juvenile Psoriatic Arthritis

A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002)

A 16-WEEK, MULTICENTER, INTERVENTIONAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ABROCITINIB IN CHILDREN 6 TO LESS THAN 12 YEARS OF AGE WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-experienced Participants With Active Psoriatic Arthritis

A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis

A Phase 4, Prospective, Open-Label, Single Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab in Adult Participants With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight in Clinical Practice

A Phase II, Multicenter, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of RO7790121 in Patients With Moderate to Severe Atopic Dermatitis

A Phase 4, Prospective, Open-Label, Single-Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab in Adult Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice.

A Multicenter Open-label, Prospective Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

A Prospective, Multi-center Observational Study Characterizing Clinical Outcomes of Patients Receiving Abrocitinib for Moderate-to-severe Atopic Dermatitis Who Had an Inadequate Response (or Intolerance) to ≤2 Previous Biologic Therapies Approved for Moderate-to-severe Atopic Dermatitis

A Phase IV, Non-randomized, Open-label Multinational Trial to Assess the Mechanism of Action for Lebrikizumab in Moderate-to-severe Atopic Dermatitis

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Platform Study to Assess the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Deucravacitinib in Adolescent Participants (12 Years to Less Than 18 Years) With Moderate to Severe Plaque Psoriasis

Phase 1b Randomized, Double Blind, Placebo-controlled Study to Evaluate Safety, Tolerability and Pharmacokinetics of LPX-TI641 in Patients With Atopic Dermatitis and Psoriasis

Sodium in the Skin and Atopic Dermatitis

The Deucravacitinib Pregnancy Exposure Study: A Prospective Observational Study of Deucravacitinib Safety in Pregnancy

A Phase I, Randomized, Double-blind, Placebo Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of ASC50 Tablets in Healthy Adult Participants and Adult Participants With Mild to Moderate Plaque Psoriasis

A Phase 2b, Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group, Dose-finding Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

A Phase 2, Parallel-arm, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of BFB759 in Patients With Atopic Dermatitis (COMPASS 2-AD)

Clinical Evaluation of the Skin Microbiome and the Efficacy of an Over-The-Counter (OTC) Drug for Atopic Dermatitis

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy and Safety of EVO756 in Adults With Atopic Dermatitis

Transforming Health Habits: Evaluating an Online Wellness Program for Individuals With Rheumatological Conditions

An Extension Study To Evaluate the Long-Term Safety and Efficacy of Afimkibart (RO7790121) in Patients With Atopic Dermatitis Who Participated in Previous Afimkibart Clinical Trials

A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-95597528 for the Treatment of Adult Participants With Moderate to Severe Atopic Dermatitis

A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Zasocitinib in Pediatric Participants Aged 4 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis

A Pilot Study to Evaluate the Safety and Tolerability of Baricitinib in Patients With Job s Syndrome With Lupus-like Disease and/or Atopic Dermatitis

A Randomized, Double-Blind, Vehicle-Controlled (Period 1) and Open-Label (Period 2) Phase 3 Study to Investigate the Safety and Efficacy of Tapinarof Cream, 1% in Pediatric Participants Ages 3 Months to < 24 Months With Atopic Dermatitis

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Moderate to Severe Atopic Dermatitis

An Open-label, Randomized, Parallel-group, Noninferiority Study to Evaluate the Pharmacokinetics of Bimekizumab Administered Intravenously or as a Subcutaneous Injection in Participants With Active Psoriatic Arthritis and/or Active Axial Spondyloarthritis

A Multicenter, Randomized, Double-blinded, Placebo-controlled, Dose-range Finding Study of ORKA-001 in Participants With Moderate-to-Severe Plaque Psoriasis

Dermatology clinical trials
recruiting in the United States